
Scandion Oncology Q2 2024 - Partnership represents best hope

Redeye comments on Scandion Oncology's Q2 2024 report, shortly after the company announced that its CORIST part 3 extension trial reached MTD. The company has intensified its partnering outreach, and we judge a potential partnership or similar is its best hope of advancing SCO-101's clinical development. Scandion raised gross proceeds of cDKK20.0m through its recent rights issue, while issue-related expenses amounted to cDKK5.9m or c30% of gross proceeds. We adjust our estimates and do some housekeeping in our model.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Scandion Oncology Q2 2024 - Partnership represents best hope](#)